GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1896 BetamethasoneSummary: Glucocorticoid receptor agonist -
B1248 Beclomethasone dipropionateSummary: Corticosteroid used for asthma and rhinitis -
B1900 Budesonide1 CitationSummary: Anti-inflammatory corticosteroid -
B1511 Mifepristone11 CitationTarget: Progesterone Receptors|Glucocorticoid ReceptorsSummary: Progesterone receptor antagonist -
C5802 CarazololSummary: high-affinity, lipophilic, non-selective ligand of the β-adrenergic receptors -
C5824 GPR120 Compound ASummary: orally available, high-affinity agonist of GPR120 -
C5743 ONO-8130Summary: orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor EP -
C5822 p-iodo-Clonidine (hydrochloride)Summary: partial agonist of the α2-adrenergic receptor -
B7929 OxomemazineSummary: Antihistamine and anticholinergic -
B7931 ButaprostSummary: Structural analog of PGE2, a selective agonist for the EP2 receptor subtype
